secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biofrontera Inc. (BFRI)
CIK:        0001858685
Form:       8-K
Filed at:   2026-03-19T23:59:59+00:00
Accession:  0001493152-26-011545
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biofrontera reports record Q4 revenue $17.1M, net income $5.6M; full-year 2025 revenue up 12% to $41.7M
--------------------------------------------------------------------------------

- Q4 2025 revenue $17.1M, up 36% YoY; net income $5.6M vs. net loss $1.4M in Q4 2024.
- Full-year 2025 revenue $41.7M, up 12% YoY; net loss narrowed to $10.5M from $17.7M.
- Gross margin improved to 82.4% in Q4 (from 58.0%) due to new earnout structure after asset purchase from Biofrontera AG.
- Adjusted EBITDA was $4.9M in Q4 vs. -$1.4M; full-year Adjusted EBITDA -$10.6M vs. -$15.3M.
- Pipeline: PDUFA date for sBCC September 2026; positive Phase 3 AK results; Phase 2b acne data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858685/000149315226011545/0001493152-26-011545-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858685/000149315226011545/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-011545

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer